atacicept

Ligand id: 9517

Name: atacicept

References
1. Cogollo E, Cogollo E, Silva MA, Isenberg D. (2015)
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus.
Drug Des Devel Ther, 9: 1331-9. [PMID:25834391]
2. Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. (2017)
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.
Arthritis Rheumatol, 69 (1): 122-130. [PMID:27390168]
3. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. (2015)
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).
Ann. Rheum. Dis., 74 (11): 2006-15. [PMID:24951103]
4. Rixon MW, Gross JA. (2002)
TACI-immunoglobulin fusion proteins.
Patent number: WO2002094852. Assignee: Zymogenetics, Inc.. Priority date: 24/05/2001. Publication date: 10/08/2003.
5. Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, Plitz T, van Beek J, ATON Trial Group. (2015)
ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis.
J. Neurol. Sci., 351 (1-2): 174-8. [PMID:25758472]
6. van Vollenhoven RF, Wax S, Li Y, Tak PP. (2015)
Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
Arthritis Rheumatol, 67 (11): 2828-36. [PMID:26137975]